Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jenga Biosciences
Carmel, Indiana, United Statesjengabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
JEN-101, a locally injected fully canine IL-12 complexed with aluminum hydroxide, showed potent biological activity and good safety in an exploratory canine melanoma study; at the pre-clinical stage with preliminary evidence for benefit in dogs with cancer[4][5].
- Therapeutic areas
- Oncology
- Modalities
- CytokineBiologic
- Industry
- Veterinary
02
Partnerships
Ankyra Therapeutics (exclusive worldwide license for JEN-101 development and commercialization)
Beyond the preview
Go deeper on Jenga Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jenga Biosciences.